TransCode Therapeutics, Inc. (RNAZ) Price to Earnings Multiple

TransCode Therapeutics, Inc. - graphic logo of issuer RNAZ

TransCode Therapeutics (RNAZ) maintains a strong position due to exclusive rights to an RNA drug delivery system for cancer and influence within government agencies, while the separate_pe metric stands at -0.60. The confirmed price history on this chart is supplemented by data regarding colossal testing costs and the complexity of scientific research. Current success is based on nanoparticles, however, long-term business sustainability depends on the final results of human trials.

transcodetherapeutics.com (RNAZ) P/E Multiple: for the period 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for TransCode Therapeutics Inc. (RNAZ)

- price and consensus price forecast:
Stock Price TransCode|RNAZ - Price Target Chart
- market capitalization details:
Market Capitalization TransCode Therapeutics, Inc.|RNAZ - Total Company Value
- issuer book value statistics:
Net Assets per Share TransCode Therapeutics|RNAZ - Book Capitalization|Market Cap to Net Assets Ratio transcodetherapeutics.com|RNAZ - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio TransCode|RNAZ - Company Aggregate Debts|Debts to Book Value TransCode Therapeutics, Inc.|RNAZ - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings TransCode Therapeutics|Intermediate Liquidity Ratio transcodetherapeutics.com
- earnings and market multiples details:
RNAZ - Net Profit|Expected Net Income TransCode Therapeutics|RNAZ - P/E Multiple|Projected Price to Earnings Ratio TransCode|RNAZ - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation TransCode Therapeutics, Inc.|RNAZ - Operating profit EBITDA|Net earnings per share (EPS TTM) TransCode Therapeutics|RNAZ - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months transcodetherapeutics.com|RNAZ - Earnings growth in current year|Expected net earnings per share growth next year TransCode Therapeutics
Summary company analysis:RNAZ (transcodetherapeutics.com)
Original product of transcodetherapeutics.com

TransCode Therapeutics (RNAZ) focuses on innovative RNA therapy methods for oncological diseases. The ratio of market capitalization to net income determines the cost of one dollar of the issuer's current earnings. Investors use this coefficient to assess whether an asset is overbought relative to its actual income. In the absence of commercial revenue and given high R&D costs, this metric often becomes negative. By analyzing the fundamental P/E of TransCode Therapeutics (RNAZ), one can evaluate the degree of speculation in current quotes.

Competing companies

P/E Multiple Tempus AI Inc|Price to Earnings Ratio Qiagen (QGEN)|Ionis Pharmaceuticals, Inc. - Price to Earnings Multiple|Price to Earnings Ratio Repligen Corp. RGEN|Business Payback Period Avidity Corp (RNA)|CRISPR Therapeutics AG - P/E Multiple|genedx.com (WGS) - Price to Earnings Ratio|Ultragenyx (RARE) - Price to Earnings Ratio|Market Cap to Earnings Beam Therapeutics Inc (BEAM)|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|Price to Earnings Multiple TWST (Twist Bioscience Corp)|P/E Multiple TXG|NTLA - Market Cap to Earnings|Stoke Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income BLFS|WVE: Price to Earnings Ratio|Maze Therapeutics Corp - Market Price to Net Income Ratio|SION: P/E Multiple|primemedicine.com - Company Value to Net Income|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MeiraGTx PLC (MGTX)|RGNX (REGENXBIO Corp) - Company Value to Net Income|P/E Multiple SLDB (Solid Biosciences Inc.)|P/E Multiple ocugen.com OCGN|PACB - Price to Earnings Ratio|Market Cap to Net Income BNTC|DSGN: P/E Multiple|Market Cap to Earnings Rocket Corp (RCKT)|Price to Earnings Ratio FDMT|P/E Multiple Lexeo|Price to Earnings Ratio KRRO (Korro Bio, Inc.)|Market Price to Net Income Ratio EDIT|P/E Multiple SLN (Silence Therapeutics Inc.)|Business Payback Period ProQR (PRQR)|Codexis Bio - P/E Multiple|sangamo.com (SGMO) - Price to Earnings Ratio|nautilus.bio (NAUT) - Price to Earnings Ratio|MGX - Business Payback Period|Price to Earnings Ratio Precision BioSciences, Inc.|GBIO: Company Value to Net Income|Price to Earnings Ratio Boundless Bio, Inc. (BOLD)|exicuretx.com - Price to Earnings Multiple|P/E Multiple IMNN (Imunon)|P/E Multiple Phio Pharmaceuticals Corp PHIO|MBIO: Price to Earnings Ratio|Market Cap to Net Income BNGO|APDN: P/E Multiple|Price to Earnings Multiple BLUE|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|P/E Multiple Regulus (RGLS)|Syros Pharmaceuticals - Price to Earnings Ratio|Market Price to Net Income Ratio TBIO (telesisbio.com)|TCON - Price to Earnings Ratio|Company Value to Net Income UBX (Unity Biotechnology Inc.)